- Home
- SDHY vs PSNL Comparison
SDHY vs PSNL Comparison
Compare SDHY & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHY
- PSNL
- Stock Information
- Founded
- SDHY 2020
- PSNL 2011
- Country
- SDHY United States
- PSNL United States
- Employees
- SDHY N/A
- PSNL N/A
- Industry
- SDHY Finance/Investors Services
- PSNL Medical Specialities
- Sector
- SDHY Finance
- PSNL Health Care
- Exchange
- SDHY Nasdaq
- PSNL Nasdaq
- Market Cap
- SDHY 396.5M
- PSNL 319.1M
- IPO Year
- SDHY N/A
- PSNL 2019
- Fundamental
- Price
- SDHY $16.58
- PSNL $4.62
- Analyst Decision
- SDHY
- PSNL Strong Buy
- Analyst Count
- SDHY 0
- PSNL 4
- Target Price
- SDHY N/A
- PSNL $6.81
- AVG Volume (30 Days)
- SDHY 94.0K
- PSNL 599.3K
- Earning Date
- SDHY 01-01-0001
- PSNL 11-05-2024
- Dividend Yield
- SDHY 8.46%
- PSNL N/A
- EPS Growth
- SDHY N/A
- PSNL N/A
- EPS
- SDHY 1.07
- PSNL N/A
- Revenue
- SDHY N/A
- PSNL $80,027,000.00
- Revenue This Year
- SDHY N/A
- PSNL $10.85
- Revenue Next Year
- SDHY N/A
- PSNL $8.77
- P/E Ratio
- SDHY $14.31
- PSNL N/A
- Revenue Growth
- SDHY N/A
- PSNL 19.20
- 52 Week Low
- SDHY $13.93
- PSNL $0.89
- 52 Week High
- SDHY $15.50
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- SDHY 56.23
- PSNL 43.01
- Support Level
- SDHY $16.47
- PSNL $4.50
- Resistance Level
- SDHY $16.69
- PSNL $5.08
- Average True Range (ATR)
- SDHY 0.15
- PSNL 0.34
- MACD
- SDHY -0.03
- PSNL -0.06
- Stochastic Oscillator
- SDHY 43.75
- PSNL 11.43
About SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return, through a combination of current income and capital appreciation. Its seeks to achieve its objective by investing in a diversified portfolio of high yield fixed income instruments.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.